{"filings":[{"id":2078637,"accession_number":"0001193125-26-335010","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-08-05T20:02:14+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 2026 revenue $26.9M (+34% YoY); net loss improves 37% to $7.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diagnostic testing revenue $25.4M (+42% YoY) on 20,900 test volumes (+38%).","Gross margin 82% (up 200 bps); operating expenses +7% vs revenue +34% shows leverage.","Net loss $7.3M (improved 37%); Adjusted EBITDA loss $3.2M (improved 56%).","FY 2026 revenue guidance maintained at $108-114M (midpoint ~25% growth); gross margin ~80%.","Cash $30.0M, up 17% from Q1 2026; includes $6.5M from ATM program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554838,"accession_number":"0001193125-26-232631","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-05-20T20:18:43+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix shareholders elect directors, approve say-on-pay, ratify KPMG at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Jean Franchi (6.19M for, 0 against, 721.8K abstain) and Hany Massarany (6.85M for, 0 against, 66.2K abstain) as Class III directors until 2029.","Non-binding advisory vote on named executive officer compensation passed: 6.62M for, 283.5K against, 11.6K abstain.","Stockholders approved 'one year' frequency for future say-on-pay votes (6.11M for one year, 777.4K for three years).","Ratified KPMG LLP as independent auditor for 2026: 8.70M for, 59 against, 2,429 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92893,"accession_number":"0001193125-26-203936","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).","Test volumes up 29% to 17,800; average revenue per test improved on expanded payer coverage and RCM enhancements.","Gross margin 82% (excl. one-time $0.4M recovery), up 300 bps YoY; net loss $7.8M (improved 30%); Adj. EBITDA loss $4.1M (improved 35%).","FY 2026 revenue guidance raised to $108-114M (from $106-112M), midpoint implies 25% growth; expects continued Adj. EBITDA improvement.","Cash $25.6M, up 35% from Dec 2025; includes $16.8M ATM net proceeds, partially offset by Q1 cash outflows."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":25555000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104096,"accession_number":"0001193125-26-076521","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.","Diagnostic test revenue $25.1M (+46% YoY), volumes 18,000 tests (+23%), average rev per test increased.","FY2025 total revenue $88.5M, above raised guidance of $84-86M; FY2026 guidance $106-112M (+23% mid-point).","First-ever positive Adj EBITDA of $0.5M in Q4; FY2025 Adj EBITDA loss $17.5M improved 21% YoY.","Post-quarter: amended Perceptive term loan to Nov 2028, raised $14.7M via ATM; pro forma cash $33.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":88499000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104095,"accession_number":"0001193125-26-010114","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K/A","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.","Lung Diagnostics revenue $25.2M in Q4 (+47% YoY), $79.2M FY (+22% YoY); test volumes 18,000 Q4, 62,600 FY.","Development Services revenue $3.6M Q4 (+13% YoY), $9.3M FY (+41% YoY).","Cash $19.0M as of Dec 31, 2025, up 14% from Q3, including $2.3M ATM proceeds; core cash flat.","Management affirms positive Adjusted EBITDA for Q4 2025 based on strong revenue flow-through."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":88499000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120372,"accession_number":"0001193125-25-262508","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).","Net loss $8.7M, a 15% improvement YoY; Adjusted EBITDA loss $4.6M, improvement of 18%.","Lung diagnostic testing revenue $19.8M (+16% YoY); Development Services $1.9M (+97% YoY).","Raised FY2025 total revenue guidance to $84-86M from prior range.","Cash $16.6M at Sept 30; accounts receivable increase $5.2M due to timing of collections."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":59744000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120371,"accession_number":"0001193125-25-226749","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biodesix regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept. 26, 2025 confirming compliance regained.","Common stock closed at $1.00+ for 10 consecutive business days.","Previously disclosed bid price deficiency on March 24, 2025.","No further action required; ongoing listing on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136946,"accession_number":"0001193125-25-203746","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Biodesix effects 1-for-20 reverse stock split, eliminates Series A preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:20 ratio effective Sep 15, 2025; new CUSIP 09075X207.","No fractional shares issued; cash-in-lieu based on closing price before effective date.","Certificate of Elimination for Series A Non-Voting Convertible Preferred filed Sep 12, 2025.","Stockholder approval obtained May 20, 2025; Board set final ratio on Sep 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136945,"accession_number":"0001193125-25-200766","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biodesix announces 1-for-20 reverse stock split effective Sept 15, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split ratio 1:20; shares outstanding drop from ~156M to ~8M.","Effective 12:01 a.m. ET Sept 15; split-adjusted trading begins at market open.","CUSIP changes to 09075X207; ticker BDSX unchanged.","Outstanding options, RSUs, and warrants proportionately adjusted; fractional shares paid in cash.","Stockholders approved at May 20, 2025 annual meeting; final ratio set by board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136944,"accession_number":"0001439725-25-000003","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).","Gross margin 80% (up 150 bps); net loss $11.5M (+6% YoY); Adjusted EBITDA loss $7.2M.","Reaffirms FY2025 revenue guidance $80-85M; aims for Adjusted EBITDA positive in Q4.","Sales team expanded to 74 reps (+21% YoY); primary care ordering up >100%; digital ordering up 63%.","Development services dollars under contract $12.5M (+54% YoY); ALTITUDE trial enrollment complete."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":37976000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154206,"accession_number":"0001193125-25-124047","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix shareholders approve reverse stock split ratio range 1:2 to 1:20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split of common stock at ratio between 1-for-2 and 1-for-20, as determined by board.","KPMG LLP ratified as independent auditor for FY 2025 with 124.9M votes for.","ESPP amended: shares available increased by 1.45M; annual automatic increase cap raised to 3.0M.","Lawrence T. Kennedy Jr. and Matthew Strobeck elected as Class II directors at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154205,"accession_number":"0000950170-25-070292","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).","Gross margin 79.4% (vs 78.6%); net loss $11.1M (improved 18% YoY); Adjusted EBITDA loss $6.2M (improved 11%).","FY2025 revenue guidance revised to $80-85M due to ~1-quarter delay in sales expansion; still expects Q4 2025 Adj. EBITDA positivity.","Drew $10M Tranche C from Perceptive Advisors loan, pro forma cash $27.6M; warrants exercise price modified to $0.4191/share.","Operating expenses $23.4M (+3% YoY): R&D up $0.9M, SG&A down 1%; non-cash stock comp fell to $1.0M from $2.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":17958000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154204,"accession_number":"0001193125-25-084319","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Biodesix directors resign effective May 20, 2025; Schuler named director emeritus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Watts, M.D. resigns from Board and Compensation Committee effective at 2025 Annual Meeting (May 20, 2025).","Jack Schuler resigns from Board and Nominating & Corporate Governance Committee, transitions to director emeritus (non-voting advisory role).","Both resignations not due to any disagreement with Company's operations, policies, or practices.","Dr. Watts served since July 2019; Mr. Schuler served since June 2008."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172801,"accession_number":"0000950170-25-046748","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biodesix receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Biodesix on March 24, 2025 that bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until September 22, 2025, to regain compliance with minimum bid price rule.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days before Compliance Date.","If not cured by Sep 22, may be eligible for additional 180-day period on Nasdaq Capital Market if other standards met.","Company may consider reverse stock split to increase bid price; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172800,"accession_number":"0000950170-25-030814","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.","Lung Diagnostic testing revenue $64.7M (+43% YoY); Biopharma Services $6.6M (+70% YoY).","Net loss $42.9M improved 18%; adjusted EBITDA loss $22.1M improved 32% vs FY2023.","Cash $26.2M at Dec 31, 2024; post-quarter amended term loan to extend $10M Tranche C availability.","FY2025 total revenue guidance $92-95M, representing 29-33% growth over FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172799,"accession_number":"0000950170-25-003717","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.","Lung Diagnostic revenue $64.7M (+43% YoY); test volumes 54,300 (+40% YoY).","Biopharma Services revenue $6.6M (+69% YoY); $12.2M contracted backlog for 2025 (+54%).","Cash and equivalents $26.2M as of Dec 31, 2024.","Results are preliminary and unaudited; Q4 and FY2024 figures subject to final audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":71323000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189811,"accession_number":"0000950170-24-119791","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).","Net loss improved 6% to $10.3M; Adjusted EBITDA loss $5.6M.","Gross profit margin 77.0% vs 76.1% in Q3 2023; test volume 13,900 (+34% YoY).","Reiterated FY 2024 revenue guidance $70M-$72M; targeting Adjusted EBITDA profitability H2 2025.","Presented Nodify XL2/CDT data at CHEST; launched CLARIFY study for diverse patient data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":50894000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206322,"accession_number":"0001193125-24-200857","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biodesix posts updated corporate presentation with no new financial or operational data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation filed under Item 7.01 and available on IR website.","Company describes itself as a blood-based lung diagnostic firm addressing large unmet need.","No specific financial figures, guidance, or clinical updates were disclosed.","Presentation contains no material new information beyond general business description."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206321,"accession_number":"0000950170-24-092722","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).","Gross margin 78.4% vs 72.7% Q2 2023; net loss improved 19% to $10.8M; Adjusted EBITDA loss improved 38% to $5.6M.","Raises full-year 2024 revenue guidance to $70-72M from prior $65-68M.","Lung diagnostic test volume 13,900, up 42% YoY and 17% sequentially.","Cash $42.2M at June 30, 2024, including $55M from April stock offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":32743000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223423,"accession_number":"0001193125-24-145965","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix shareholders elect three Class I directors and approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jon Faiz Kayyem, Scott Hutton, and John Patience elected as Class I directors with over 79M votes each.","Ratification of KPMG as independent auditor for FY2024 approved (88.3M for, 167K against).","Conversion of Series A Preferred Stock into common stock approved (82.4M for, 5.8K abstain).","Issuance of Series A Preferred Stock to directors/officers approved (82.3M for, 437K against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223422,"accession_number":"0000950170-24-055608","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).","Gross margin 79% vs 65% YoY; net loss improved 27% to $13.6M.","Adjusted EBITDA loss $7.0M, improvement of 48% from $13.4M loss in Q1 2023.","Raised $55M gross proceeds in April 2024 oversubscribed offering; cash $11.5M at Q1 end excluding proceeds.","Reaffirmed 2024 revenue guidance of $65M-$68M; new collaboration with MSKCC for cancer diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":14818000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223421,"accession_number":"0001193125-24-090787","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Biodesix raises ~$51.6M in oversubscribed common offering and convertible preferred placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds ~$51.6M from 17.4M shares common at $1.15/share and 760,857 Series A Preferred at $46/share.","Series A Preferred automatically converts to 40 common shares per preferred share upon stockholder approval, up to 30.4M common shares.","Management and directors participated in the private placement; 90-day lock-up on common shares.","Funds to be used for commercial expansion, product pipeline, R&D, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242867,"accession_number":"0000950170-24-023509","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q4 revenue $14.7M (+53% YoY); guides FY2024 revenue $65-$68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenue $49.1M, +28% YoY; Lung Diagnostic test volume up 65%.","Q4 gross margin 77% vs 66% a year ago; net loss improved 55% to $9.1M.","FY2023 Adjusted EBITDA loss $32.7M, improved 24% YoY.","Cash $26.3M at Dec 31, 2023; drew $10M second tranche from Perceptive term loan.","FY2024 revenue guidance $65-$68M, representing 32%-39% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260236,"accession_number":"0000950170-23-071761","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Biodesix draws $10M Tranche B loan from Perceptive; issues 1M-share warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $10M Tranche B under existing $50M Perceptive term loan facility on Dec 15, 2023.","Interest rate is greater of 1-month term SOFR or 3% plus 9.0% margin; maturity Nov 21, 2027.","Issued Tranche B Warrants for 1,000,000 shares at $1.0648 per share, expiring Dec 15, 2033.","Facility is secured by first lien on substantially all assets; must maintain $2.5M minimum cash and revenue milestones.","Tranche C of up to $10M remains available subject to conditions; no other material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260235,"accession_number":"0000950170-23-060209","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 2023: Lung diagnostic revenue up 34% YoY; net loss narrows 20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $13.5M (+21% YoY); lung diagnostics $12.3M (+34% YoY); Biopharma Services $1.2M (+79% YoY).","Lung diagnostic test volume >10,400 (+60% YoY); gross margin improved to 76% from 67%.","Net loss $10.9M (-20% YoY); Adjusted EBITDA loss $5.4M (-40% YoY).","FY 2023 revenue guidance lowered to $50-52M due to Medicare Advantage backlog removal; core business unchanged.","Cash $19.8M at Sep 30; additional $10M draw from Perceptive term loan and final $12.2M private placement expected in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":34419000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277527,"accession_number":"0000950170-23-039049","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 core lung diagnostics revenue up 58% YoY to $11.4M; raises $27.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core lung diagnostic revenue $11.4M (+58% YoY, +33% QoQ); gross margin 73% vs 64% in Q2 2022.","Net loss $13.4M improved 16% YoY; cash burn reduced 56% QoQ to $7.9M.","Raised $27.5M in private placement post-quarter from largest shareholders, board, and management.","Reaffirmed FY2023 total revenue guidance of $52-55M.","Achieved primary endpoint of ORACLE study: 74% reduction in unnecessary procedures using Nodify XL2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":20928000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277526,"accession_number":"0001193125-23-194600","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biodesix completes stock option exchange; net reduction of ~600K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["83 employees exchanged options; 757,595 shares cancelled (~99% of eligible).","New options granted for 156,868 shares at exercise price of $1.20 per share.","Net reduction in potential dilution of approximately 600,727 shares.","New options vest per terms of Exchange Offer and 2020 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295480,"accession_number":"0001193125-23-161649","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biodesix appoints Christopher Vazquez as CAO, replacing Ryan Siurek effective July 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Siurek resigned as Chief Accounting Officer, effective July 3, 2023; no disagreement with company.","Christopher Vazquez, previously VP and Controller since Feb 2021, appointed as CAO effective same date.","Vazquez will report to CFO; compensation includes equity and annual cash incentive plans per proxy statement.","No family relationships or related-party transactions between Vazquez and company officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295479,"accession_number":"0001193125-23-154219","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix stockholders elect three directors, ratify KPMG, approve option exchange at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class III director nominees (Jean Franchi, Hany Massarany, Jack Schuler) elected with >62M votes each.","Ratification of KPMG as independent auditor for FY2023 passed: 71.4M for, 95,555 against, 28,164 abstentions.","Stock option exchange program approved: 60.4M for, 4.2M against, 19,570 abstentions, 6.9M broker non-votes.","Record date March 24, 2023; 77,979,011 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295478,"accession_number":"0000950170-23-021281","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $9.1M (+38% YoY); core lung diagnostics up 86% to $8.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.1M, +38% YoY; core lung diagnostic revenue $8.6M, +86% YoY.","Net loss $18.7M ($0.24 per share); operating expenses $22.3M up 25% YoY.","Gross margin improved to 65% from 51% due to shift from lower-margin COVID-19 tests.","COVID-19 testing revenue down 99% YoY; company discontinues commercial COVID-19 testing.","Reaffirmed 2023 total revenue guidance $52M-$55M; cash $25.3M as of March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":9056000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316024,"accession_number":"0000950170-23-006084","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q4 core lung diag revenue $8.2M (+51% YoY); guides 2023 total rev $52-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q4 $9.6M, FY2022 $38.2M; core lung diagnostic revenue $29.3M (+57% YoY).","Net loss Q4 $20.3M, FY2022 $65.4M; includes $7.0M loss on debt extinguishment/modification.","Cash and equivalents $43.1M at Dec 31, 2022; raised $65.7M net from debt/equity in Q4.","2023 total revenue guidance $52-55M, representing 36-44% growth over 2022 total revenue.","Biopharma services revenue $3.7M in FY2022 (-34% YoY); highest dollars under contract entering 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334327,"accession_number":"0000950170-22-026669","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biodesix appoints Lawrence T. Kennedy to Board of Directors, effective Jan 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kennedy appointed to Board and Audit Committee, effective Jan 3, 2023.","He brings 20+ years healthcare operating, finance, and investment experience; managing partner/CEO of Westwood Management.","Initial equity grant of $375K (50% NQSOs, 50% RSUs) plus prorated annual grant of $46,411 in RSUs.","Senior Mgmt Bonus to Equity Plan amended: Multiplier reduced from 4 to 3, and Company may limit election by percentage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334326,"accession_number":"0000950170-22-025530","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Biodesix raises $70.7M via $50M term loan and $40.3M equity; retires $24M in debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $50M Perceptive term loan; $30M drawn at close, two $10M tranches available on revenue milestones.","Priced public offering of 35.075M shares at $1.15; gross proceeds $40.3M; net ~$37.5M.","Used $24M of net proceeds to repay Streeterville note ($18.2M) and SVB term loan ($5.8M).","Loan is interest-only for 5 years at SOFR (floor 3%) + 9%; matures Nov 2027; warrants for up to 5M shares at $1.0648.","Management purchased 278,514 shares at $1.15 in a private placement; lock-up 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334325,"accession_number":"0000950170-22-021479","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 core lung diagnostic revenue up 102% to $9.2M; guidance at high end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core lung diagnostic revenue $9.2M (+102% YoY); total revenue $11.1M (+70% YoY).","Gross margin 67% vs 58% YoY, driven by growth in higher-margin core lung diagnostics.","Net loss $13.7M (up 19% YoY); cash $15.2M; raised $1.8M via equity; repaid $2.0M term loan.","All five core lung tests now covered by Medicare; added to Federal Supply Schedule for VA and Military Health.","2022 total revenue guidance expected at high end of $37.5M-$39.5M; minimal COVID/BioPharma in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":28605000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334324,"accession_number":"0000950170-22-019405","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix preliminary Q3 revenue $10.6M-$11.2M, core lung diagnostics up 96-103% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 2022 revenue estimated $10.6M-$11.2M, up 62-71% YoY.","Core lung diagnostic testing revenue $8.9M-$9.2M, a 96-103% increase YoY.","COVID testing revenue $1.1M-$1.3M, up 117-157% YoY; expects immaterial in Q4.","Biopharma services revenue $0.6M-$0.7M, down 53-60% YoY due to clinical study delays.","Cash and equivalents $15.2M as of Sep 30; expects FY2022 revenue near high end of $37.5M-$39.5M guidance range."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":28605000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351753,"accession_number":"0000950170-22-014426","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 core lung diag revenue $7.3M (+52% YoY); net loss $15.8M; reaffirms 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core lung diagnostic revenue $7.3M, up 52% YoY; total revenue $11.0M down 8% due to COVID test decline.","Net loss $15.8M, up 39% driven by loss on extinguishment from Indi contingent consideration restructuring.","Cash and equivalents $28.7M (incl. $5.1M restricted); raised net $27.3M in debt/equity during Q2.","Reaffirmed 2022 revenue outlook of $37.5M-$39.5M; Medicare coverage secured for Nodify CDT test.","Announced strategic pacts with Philips, MSK, and Bio-Rad to co-develop an MRD test for solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":17498000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369190,"accession_number":"0001193125-22-159676","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix stockholders elect two Class II directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Matthew Strobeck, Ph.D. and Charles Watts, M.D. elected as Class II directors (23.1M votes for each).","KPMG LLP ratified as independent auditor for FY2022 with 26.5M votes for, 14,941 against.","31,839,317 shares outstanding as of record date March 25, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369189,"accession_number":"0000950170-22-009124","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 core lung diag rev $4.6M (+17% YoY); net loss $15.6M; raised $27.4M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core lung diagnostic revenue $4.6M (+17% YoY); total revenue $6.5M (-77% YoY) as COVID-19 testing fell 96%.","Net loss $15.6M (increase 124% YoY); operating expenses $17.8M, up 10%.","Raised $27.4M post-Q1: $11.7M private placement, $2.7M ATM, $13M net from $25M debt facility.","Restructured Indi milestone payments, reducing 2022 pay by $7.5M and 2023 by $7.2M.","Reaffirmed FY2022 total revenue outlook of $37.5M-$39.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":6548000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369188,"accession_number":"0000950170-22-005536","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Biodesix raises $11.7M via private placement; amends 2021 term loan with SVB","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sold 6,508,376 shares at $1.79/share to consortium including board members, raising ~$11.7M.","Third Amendment to 2021 Term Loan: repays $3M in April 2022 and $2M later; waives Q1 2022 minimum revenue requirement.","Waiver of prepayment fee on $3M repayment; consent for $2M milestone payment under Integrated Diagnostics purchase agreement.","Reaffirms 2022 revenue guidance of $37.5M-$39.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388399,"accession_number":"0000950170-22-003491","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix reports FY2021 revenue $54.5M; core lung diagnostic up 49% YoY to $18.7M; net loss $43.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $7.2M; core lung diagnostic revenue $5.4M (+48% YoY); BioPharma services $1.4M (-29% YoY).","FY2021 total revenue $54.5M; core lung diagnostic $18.7M (+49% YoY); COVID-19 testing revenue $30.2M (+7% YoY).","Q4 gross margin 65% vs 46% YoY driven by mix shift to higher-margin lung diagnostics; operating expenses $16.4M.","Net loss Q4 $13.3M (increase of 193% YoY); FY2021 net loss $43.2M (increase 38% YoY).","Guides FY2022 total revenue $37.5M-$39.5M; cash $32.7M after $20M debt prepayment and $15.7M equity raise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388398,"accession_number":"0000950170-22-003002","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biodesix enters $50M common stock purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M of common stock may be sold to Lincoln Park over 36 months at Biodesix's discretion.","Purchase price based on prevailing market prices with no upper limit per share.","No warrants, derivatives, financial or business covenants; LPC cannot short or hedge.","Biodesix issued commitment shares as a fee and can terminate the agreement at any time without cost.","Net proceeds to be used for growth strategy and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388397,"accession_number":"0000950170-22-001168","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix reports record full-year 2021 revenue of $54.5M; core lung diagnostic testing up 49%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Full-year 2021 total revenue $54.5M vs $45.6M in 2020; Q4 revenue $7.2M.","Core lung diagnostic testing revenue grew 49% YoY; excluding COVID-19, annual core revenue $24.3M (+41%).","Q4 core revenue (ex-COVID) $6.8M, up 22% YoY and 13% sequentially.","Cash and cash equivalents $32.7M as of Dec 31, 2021.","CEO highlights new IQLung and GeneStrat NGS tests; company may seek additional capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":54506000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388396,"accession_number":"0000950170-22-001157","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix reports preliminary Q4 2021 revenue of $7.2M; core lung testing grows 49% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2021 total revenue of $54.5M, up from $45.6M in 2020.","Core lung diagnostic testing revenue grew 49% for full-year 2021.","Quarterly revenue excluding COVID-19 testing was $6.8M, up 22% YoY and 13% QoQ.","Annual revenue excluding COVID-19 testing was $24.3M, up 41% YoY.","Cash and cash equivalents as of Dec 31, 2021: $32.7M; exploring raising capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":54506000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388395,"accession_number":"0000950170-22-000036","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biodesix raises ~$16.3M via ATM equity sale, repays $20M of term loan with SVB","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Raised ~$16.3M from sale of 3,756,994 common shares in ATM offering on Dec 30, 2021.","Entered Consent and Second Amendment to $30M 2021 Term Loan with Silicon Valley Bank on Dec 31, 2021.","Repaid $20M in outstanding principal on Dec 31; $600,000 prepayment fee waived.","Amendment consents to $4.6M milestone payment under Integrated Diagnostics APA in Jan 2022.","Company cites improved financial flexibility to advance strategic growth objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406325,"accession_number":"0000950170-21-005077","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2021-12-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biodesix appoints Dr. Jon Faiz Kayyem to board of directors effective December 6, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kayyem brings 20+ years experience in molecular diagnostics, having founded GenMark Diagnostics and Clinical Micro Sensors.","Initial equity grant of $375,000: 50,368 NQSOs (5-year vest) and 31,619 RSUs (1-year vest).","Prorated annual grant of $87,397: 27,038 NQSOs vesting March 31, 2022, strike at close on December 7, 2021.","Appointed to Compensation Committee effective December 7, 2021; term expires at 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406324,"accession_number":"0001564590-21-056810","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 lung diagnostic revenue up 51% YoY; launches 72-hour NGS test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.5M; lung diagnostic revenue $4.5M (+51% YoY), services $1.5M (+133%), COVID-19 testing $0.5M (-91%).","Gross margin 58% (up from 40% in Q2 2021); operating expenses $16.9M (+46%).","Net loss $11.5M (+30%); includes $3.1M non-cash PPP loan forgiveness gain.","Cash and cash equivalents $47.9M as of Sept 30, 2021.","Launched 72-hour liquid NGS test ahead of schedule; broad US launch targeted for Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":47282000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425346,"accession_number":"0001564590-21-047416","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biodesix posts corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation posted on investor relations website dated September 9, 2021.","Presentation contains forward-looking statements and no new financial guidance or material events.","No changes to previously disclosed business operations or outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425345,"accession_number":"0001564590-21-043064","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 total revenue $11.9M (+180%), core lung diagnostics $4.8M (+109%); NGS test launch accelerated to Q1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.9M (+180% YoY); core lung diagnostic revenue $4.8M (+109%).","COVID-19 testing revenue $6.1M (+345%) but declining sequentially; net loss $11.4M (+38%).","Gross profit $4.8M (40% margin); operating expenses $15.4M (+93%) due to sales force buildout.","Nodify XL2 milestone triggers $37M obligation payable over six quarterly installments starting Jan 2022.","Accelerated launch of 72-hour liquid NGS test to Q1 2022; cash $56.3M; expects $3.1M PPP loan forgiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":40751000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}